208 related articles for article (PubMed ID: 36112781)
1. A Probody T Cell-Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity.
Boustany LM; LaPorte SL; Wong L; White C; Vinod V; Shen J; Yu W; Koditek D; Winter MB; Moore SJ; Mei L; Diep L; Huang Y; Liu S; Vasiljeva O; West J; Richardson J; Irving B; Belvin M; Kavanaugh WM
Cancer Res; 2022 Nov; 82(22):4288-4298. PubMed ID: 36112781
[TBL] [Abstract][Full Text] [Related]
2. Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody.
Geiger M; Stubenrauch KG; Sam J; Richter WF; Jordan G; Eckmann J; Hage C; Nicolini V; Freimoser-Grundschober A; Ritter M; Lauer ME; Stahlberg H; Ringler P; Patel J; Sullivan E; Grau-Richards S; Endres S; Kobold S; Umaña P; Brünker P; Klein C
Nat Commun; 2020 Jun; 11(1):3196. PubMed ID: 32581215
[TBL] [Abstract][Full Text] [Related]
3. Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology.
Autio KA; Boni V; Humphrey RW; Naing A
Clin Cancer Res; 2020 Mar; 26(5):984-989. PubMed ID: 31601568
[TBL] [Abstract][Full Text] [Related]
4. A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.
Gedeon PC; Schaller TH; Chitneni SK; Choi BD; Kuan CT; Suryadevara CM; Snyder DJ; Schmittling RJ; Szafranski SE; Cui X; Healy PN; Herndon JE; McLendon RE; Keir ST; Archer GE; Reap EA; Sanchez-Perez L; Bigner DD; Sampson JH
Clin Cancer Res; 2018 Aug; 24(15):3611-3631. PubMed ID: 29703821
[No Abstract] [Full Text] [Related]
5. A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.
Bacac M; Fauti T; Sam J; Colombetti S; Weinzierl T; Ouaret D; Bodmer W; Lehmann S; Hofer T; Hosse RJ; Moessner E; Ast O; Bruenker P; Grau-Richards S; Schaller T; Seidl A; Gerdes C; Perro M; Nicolini V; Steinhoff N; Dudal S; Neumann S; von Hirschheydt T; Jaeger C; Saro J; Karanikas V; Klein C; Umaña P
Clin Cancer Res; 2016 Jul; 22(13):3286-97. PubMed ID: 26861458
[TBL] [Abstract][Full Text] [Related]
6. JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy.
Leclercq G; Haegel H; Toso A; Zimmermann T; Green L; Steinhoff N; Sam J; Pulko V; Schneider A; Giusti AM; Challier J; Freimoser-Grundschober A; Larivière L; Odermatt A; Stern M; Umana P; Bacac M; Klein C
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35064010
[TBL] [Abstract][Full Text] [Related]
7. Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody-Drug Conjugate.
Singh S; Serwer L; DuPage A; Elkins K; Chauhan N; Ravn M; Buchanan F; Wang L; Krimm M; Wong K; Sagert J; Tipton K; Moore SJ; Huang Y; Jang A; Ureno E; Miller A; Patrick S; Duvur S; Liu S; Vasiljeva O; Li Y; Henriques T; Badagnani I; Jeffries S; Schleyer S; Leanna R; Krebber C; Viswanathan S; Desnoyers L; Terrett J; Belvin M; Morgan-Lappe S; Kavanaugh WM; Richardson J
Mol Cancer Ther; 2022 Aug; 21(8):1326-1336. PubMed ID: 35666803
[TBL] [Abstract][Full Text] [Related]
8. In vivo imaging of protease activity by Probody therapeutic activation.
Wong KR; Menendez E; Craik CS; Kavanaugh WM; Vasiljeva O
Biochimie; 2016 Mar; 122():62-7. PubMed ID: 26546838
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index.
Desnoyers LR; Vasiljeva O; Richardson JH; Yang A; Menendez EE; Liang TW; Wong C; Bessette PH; Kamath K; Moore SJ; Sagert JG; Hostetter DR; Han F; Gee J; Flandez J; Markham K; Nguyen M; Krimm M; Wong KR; Liu S; Daugherty PS; West JW; Lowman HB
Sci Transl Med; 2013 Oct; 5(207):207ra144. PubMed ID: 24132639
[TBL] [Abstract][Full Text] [Related]
10. A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell-Mediated Immune Response against EGFR-Expressing Tumors.
King LA; Toffoli EC; Veth M; Iglesias-Guimarais V; Slot MC; Amsen D; van de Ven R; Derks S; Fransen MF; Tuynman JB; Riedl T; Roovers RC; Adang AEP; Ruben JM; Parren PWHI; de Gruijl TD; van der Vliet HJ
Cancer Immunol Res; 2023 Sep; 11(9):1237-1252. PubMed ID: 37368791
[TBL] [Abstract][Full Text] [Related]
11. A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy.
Frey G; Cugnetti APG; Liu H; Xing C; Wheeler C; Chang HW; Boyle WJ; Short JM
MAbs; 2024; 16(1):2322562. PubMed ID: 38445633
[TBL] [Abstract][Full Text] [Related]
12. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.
Ishiguro T; Sano Y; Komatsu SI; Kamata-Sakurai M; Kaneko A; Kinoshita Y; Shiraiwa H; Azuma Y; Tsunenari T; Kayukawa Y; Sonobe Y; Ono N; Sakata K; Fujii T; Miyazaki Y; Noguchi M; Endo M; Harada A; Frings W; Fujii E; Nanba E; Narita A; Sakamoto A; Wakabayashi T; Konishi H; Segawa H; Igawa T; Tsushima T; Mutoh H; Nishito Y; Takahashi M; Stewart L; ElGabry E; Kawabe Y; Ishigai M; Chiba S; Aoki M; Hattori K; Nezu J
Sci Transl Med; 2017 Oct; 9(410):. PubMed ID: 28978751
[TBL] [Abstract][Full Text] [Related]
13. Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.
Zuch de Zafra CL; Fajardo F; Zhong W; Bernett MJ; Muchhal US; Moore GL; Stevens J; Case R; Pearson JT; Liu S; McElroy PL; Canon J; Desjarlais JR; Coxon A; Balazs M; Nolan-Stevaux O
Clin Cancer Res; 2019 Jul; 25(13):3921-3933. PubMed ID: 30918018
[TBL] [Abstract][Full Text] [Related]
14. p95HER2-T cell bispecific antibody for breast cancer treatment.
Rius Ruiz I; Vicario R; Morancho B; Morales CB; Arenas EJ; Herter S; Freimoser-Grundschober A; Somandin J; Sam J; Ast O; Barriocanal ÁM; Luque A; Escorihuela M; Varela I; Cuartas I; Nuciforo P; Fasani R; Peg V; Rubio I; Cortés J; Serra V; Escriva-de-Romani S; Sperinde J; Chenna A; Huang W; Winslow J; Albanell J; Seoane J; Scaltriti M; Baselga J; Tabernero J; Umana P; Bacac M; Saura C; Klein C; Arribas J
Sci Transl Med; 2018 Oct; 10(461):. PubMed ID: 30282693
[TBL] [Abstract][Full Text] [Related]
15. Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies.
Leclercq G; Haegel H; Schneider A; Giusti AM; Marrer-Berger E; Boetsch C; Walz AC; Pulko V; Sam J; Challier J; Ferlini C; Odermatt A; Umaña P; Bacac M; Klein C
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326166
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors.
Wingert S; Reusch U; Knackmuss S; Kluge M; Damrat M; Pahl J; Schniegler-Mattox U; Mueller T; Fucek I; Ellwanger K; Tesar M; Haneke T; Koch J; Treder M; Fischer W; Rajkovic E
MAbs; 2021; 13(1):1950264. PubMed ID: 34325617
[TBL] [Abstract][Full Text] [Related]
17. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
18. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.
Yu S; Zhang J; Yan Y; Yao X; Fang L; Xiong H; Liu Y; Chu Q; Zhou P; Wu K
J Exp Clin Cancer Res; 2019 Aug; 38(1):355. PubMed ID: 31412896
[TBL] [Abstract][Full Text] [Related]
19. Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers.
Wu Z; Guo HF; Xu H; Cheung NV
Mol Cancer Ther; 2018 Oct; 17(10):2164-2175. PubMed ID: 30082472
[TBL] [Abstract][Full Text] [Related]
20. Development of T-cell engagers selective for cells co-expressing two antigens.
Dicara DM; Bhakta S; Go MA; Ziai J; Firestein R; Forrest B; Gu C; Leong SR; Lee G; Yu SF; Polson AG; Agard NJ
MAbs; 2022; 14(1):2115213. PubMed ID: 36206404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
